**Nerlynx: A Case-based Discussion on HER2+ Early-Stage**

**Breast Cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  **PRESENTED BY:****Puma Biotechnology** | **Sosy Fincher RN, MSN, AOCN**Clinical Nurse Educator |  |  |
|  |  |  |  |
|  **PROGRAM INFORMATION:** |  **Wednesday, September 11, 2024 @ 6:00p****Restaurant****Fleming's Prime Steakhouse & Wine Bar Santa Clara****2762 Augustine Dr Ste 110****Santa Clara, CA 95054** |  |  |

**Program Featuring:**

* Clinical case studies based on actual NERLYNX patients with HER2+ eBC with and without a pCR
* Review strategies to help mitigate diarrhea associated with NERLYNX
* Discuss dose escalation and treatment duration with NERLYNX

**TO REGISTER OR 9OR QUESTIONS PLEASE EMAIL SVONS**

**Please register with SVONS by 9/4/2024 as space is limited.**

**For additional information please contact Robin Gingold at rgingold@pumabiotechnology.com**

**Registration assures your spot and assists Puma Biotechnology with holding efficient programs.**

**Details will be provided after registration.> OR < In accordance with the PhRMA Code of Ethics, alcohol will not be provided at this educational program>**

Certain states, government agencies, and institutions (e.g., New Jersey, Minnesota, Vermont, the Department of Defense, and the Department of Veterans Affairs) may restrict you from receiving in-kind benefits (e.g., meals) at industry-sponsored events. You are accountable for understanding any such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, please do not partake in the in-kind benefits provided by Puma Biotechnology, Inc. All attendees are advised that information such as your name, the purpose, and the value of any items (e.g., food and beverage) provided to you by Puma Biotechnology, Inc. may be publicly disclosed.

This program is sponsored by Puma Biotechnology, Inc. This is not an independent educational program, and no CME credits will be provided.

# INDICATIONS:

**NERLYNX® (neratinib) tablets, for oral use**, is a kinase inhibitor indicated:

* As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
* In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

**Please see Important Safety Information on next page and accompanying** [**Full Prescribing Information**](https://nerlynxhcp.com/pdf/full-prescribing-information.pdf) **including** [**Patient Information.**](https://nerlynx.com/pdf/patient-information.pdf)

**NERLYNX® (neratinib) tablets, for oral use**

# IMPORTANT SAFETY INFORMATION

**CONTRAINDICATIONS:** None

### WARNINGS AND PRECAUTIONS:

* **Diarrhea:** Manage diarrhea through either NERLYNX dose escalation or loperamide prophylaxis. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥2 diarrhea that occurs after maximal dose reduction.
* **Hepatotoxicity:** Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.
	+ **Embryo-Fetal Toxicity:** NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

**ADVERSE REACTIONS:** The most common adverse reactions (reported in ≥ 5% of patients) were:

* + NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.
	+ NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/ asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

**To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or** [***www.fda.gov/medwatch*.**](http://www.fda.gov/medwatch)

### DRUG INTERACTIONS:

* + Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists. Or separate NERLYNX by at least 3 hours after antacids.
	+ Strong CYP3A4 inhibitors: Avoid concomitant use.
	+ P-gp and moderate CYP3A4 dual inhibitors: Avoid concomitant use.
	+ Strong or moderate CYP3A4 inducers: Avoid concomitant use.
	+ Certain P-gp substrates: Monitor for adverse reactions of P-gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with NERLYNX.

### USE IN SPECIFIC POPULATIONS:

* + **Lactation:** Advise women not to breastfeed.

## Please see accompanying [Full Prescribing Information](https://nerlynxhcp.com/pdf/full-prescribing-information.pdf) including [Patient Information.](https://nerlynx.com/pdf/patient-information.pdf)

ALT = alanine aminotransferase; AST = aspartate aminotransferase; HER2 = human epidermal growth factor receptor 2; pCR = pathological complete response

NERLYNX is a registered trademark of Puma Biotechnology, Inc.

©2023 Puma Biotechnology, Inc. All Rights Reserved. PRC-US-NER-3078; 06/2025